200-2016-89085_Contract_GSK_signed_03302016.pdf

Page i

TABLE OF CONTENTS

Section Document/Clause/Provision Page No.

A Standard Form 1449 B Continuation of SF1449 (Block 19 – 24) 1 C Contract Clauses 6 D Contract Documents, Exhibits or Attachments 22

Contract No. 200-2016-88085

SECTION B - CONTINUATION OF SF1449

ITEM SUPPLIES / SERVICES QTY / UNIT UNIT PRICE EXTENDED PRICE

0001 VFC Vaccines

1 Lot $760,961,520.00 $760,961,520.00

Line(s) Of Accounting:

93904X0 2611 2016 75-75-X-0512-0 2004111101 $173,860,820.38

0002 317/PPHF Vaccines

1 Lot $190,240,380.00 $190,240,380.00

Line(s) Of Accounting:

93905C5 2611 2016 75-X-0951 H008D11101 $713,512.69

Total Estimated Contract Value $951,201,900.00

Notes:

B.1 The total estimated value of this contract is $951,201,900.00. The funded amount of this contract is currently $174,574,333.07, which represents the Government’s maximum liability for this contract.

The following table shows the exact allocation of this amount in VFC and PPHF purchase funds:

Type of Action VFC Funds 317 Funds PPHF Funds Stockpile Funds

Award $ 173,860,820.38 $ ‐ $ 713,512.69 $ ‐

B.2 Funded Amount: The table below shows the vaccines to be purchased with these newly added funds. Actual vaccines and quantities may vary. Specific delivery orders will be placed through the CDC electronic ordering system on a weekly basis.

Vaccine VFC Purchase Amount

VFC

Doses

317/PPHF

Purchase Amount

317/PPHF

Doses

DTAP $ 8,130,344.05 482,513 $ 17,827.30 1,058

DTAPHBIP $ 27,697,928.40 504,516 $ 119,462.40 2,176

DTaPIPV $ 19,389,616.56 490,008 $ 1,622.37 41

HEP A $ 11,704,164.73 656,431 $ 1,390.74 78

HEP B‐PF $ 8,439,162.40 727,514 $ 393,008.00 33,880

HIB $ 946.00 100 $ ‐ 0

MCV2‐HIB $ 5,949.45 565 $ 136.89 13

ROTA $ 23,923,915.00 275,780 $ 1,735.00 20

TDAP $ 16,819,849.02 525,949 $ 32,107.92 1,004

HEP AB18 $ 55,405.35 1,001 $ ‐ 0

MCV4 $ 35,063,854.22 411,451 $ 5,198.42 61

MenB $ 22,629,685.20 184,056 $ 141,023.65 1,147

TOTAL $ 173,860,820.38 $ 713,512.69

B.3 Type of Contract: This is a firm-fixed price, indefinite delivery/indefinite quantity delivery contract for the purchase of standard commercial vaccines described herein, manufactured under a current establishment and product license issued by the U.S. Food and Drug Administration (FDA) and as otherwise set forth herein.

B.4 Background: The Centers for Disease Control and Prevention (CDC) awards contracts for the purchase of standard commercial pediatric vaccines. Vaccines are one of the most cost-effective ways to prevent disease and reduce healthcare costs. The Vaccine for Children (VFC) program, established pursuant to Section 13631 of the Omnibus Budget Reconciliation Act of 1993 (OBRA ’93), guarantees federal support for the purchase and supply of sufficient quantities of vaccine to the States to cover a defined group of children. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage. Children (18 years-of-age or younger) who qualify for immunization through the VFC purchase program include those who are (1) Medicaid-eligible, (2) without health insurance, (3) American Indian/Alaska native (as defined in Subsection (h)(3) of the OBRA ’93), or (4) children with health insurance, which does not cover the cost of vaccines, if they receive their immunizations at a Federally-qualified health center or rural health clinic (as defined by the Social Security Act). Health care providers who agree to certain requirements are eligible through the States to receive free vaccine through this VFC purchase program.

The vaccines awarded under these contracts provides an opportunity for the 64 immunization

Awardees (includes State health departments and certain local health agencies authorized to order hereunder) as provided under OBRA '93 and Section 317(j) of the Public Health Service Act. In addition, States may opt to purchase additional quantities of vaccine using State funds under 42 USC §1396s(d)(4)(B) under any resulting contract to provide immunizations only for children who are not federally vaccine-eligible.

B.5 Definitions:

OBRA Orders – Vaccine orders under Section 1928(a) (2) (A) of the Social Security Act.

317 Orders – Vaccine orders under Section 317(j) of the Public Health Service Act

State and Local Orders – Vaccine orders placed by authorized immunization programs using state or local funds in accordance with Section 1928(d)(4)(B) of the Social Security Act

Manufacturer – As defined in Subsection (h) (4) of the Social Security Act, means any corporation, organization, or institution, whether public or private, which Manufacturers, imports, processes, or distributes under its label any pediatric vaccine

Awardees – Includes State health departments and certain local health agencies authorized to order hereunder.

B.6 Minimum and Maximum Order Limitations: The following table covers the minimum and maximum order limitations for the pediatric vaccines awarded under this contract

ITEM SUPPLIES / SERVICES QTY / UNIT UNIT PRICE EXTENDED PRICE

1. DTaP vaccine: Infanrix

Min. Shelf Life: 12 Months Maximum Quantity: 2,270,000 Doses Guaranteed Minimum: 100 Doses Minimum Order Size: 100 Doses

NDC # 58160-0810-11

570,000 Doses

NDC # 58160-0810-52:

1,700,000 Doses Fed. Excise Tax: $2.25 per dose

2,270,000 Doses $16.85 (with FET included)

$38,249,500.00

2. DTaP/Hep B/IPV vaccine: Pediarix Min. Shelf Life: 12 Months Maximum Quantity: 4,500,000 Doses Guaranteed Minimum: 100 Doses Minimum Order Size: 100 Doses

NDC # 58160-0811-52

Fed. Excise Tax: $3.75 per dose

4,500,000 Doses

$54.90 (with FET

$247,050,000.00

3. DTaP-IPV Vaccine: Kinrix Min. Shelf Life: 12 months Maximum Quantity: 2,280,000 Doses Guaranteed Minimum: 100 Doses Minimum Order Size: 100 Doses

NDC # 58160-0812-11

880,000 Doses

NDC # 58160-0812-52

1,400,000 Doses Fed. Excise Tax: $3.00 per dose

2,280,000 Doses $39.57 (with FET

$90,219,600.00

4. Hepatitis A (pediatric) vaccine: Havrix Min. Shelf Life: 12 Months Maximum Quantity: 5,250,000 Doses Guaranteed Minimum: 100 Doses Minimum Order Size: 100 Doses

NDC # 58160-0825-11

1,500,000 Doses

NDC # 58160-0825-52

3,750,000 Doses Fed. Excise Tax: $0.75 per dose

5,250,000 Doses $17.83 (with FET

$93,607,500.00

5. Hepatitis A&B (Age 18 only) vaccine:

Twinrix Min. Shelf Life: 12 Months Maximum Quantity: 20,000 Doses Guaranteed Minimum: 100 Doses Minimum Order Size: 100 Doses

NDC # 58160-0815-52

20,000 Doses Fed. Excise Tax: $1.50 per dose

20,000 Doses $55.35 (with FET

$1,107,000.00

6. Hepatitis B (pediatric/adol.) vaccine:

Engerix B Min. Shelf Life: 12 Months Maximum Quantity: 2,700,000 Doses Guaranteed Minimum: 100 Doses

2,700,000 Doses $11.60 (with FET

$31,320,000.00

Minimum Order Size: 100 Doses

NDC # 58160-0820-11

1,000,000 Doses

NDC # 58160-0820-52

1,700,000 Doses Fed. Excise Tax: $0.75 per dose

7. Hib Vaccine: Hiberix Min. Shelf Life: 12 Months Maximum Quantity: 1,700,000 Doses Guaranteed Minimum: 100 Doses Minimum Order Size: 100 Doses

NDC # 58160-0818-11

1,700,000 Doses

$9.46 (with FET

$16,082,000.00

8. Menigococcal Conjugate Vaccine (MCV4): Menveo Min. Shelf Life: 12 Months Maximum Quantity: 1,400,000 Doses Guaranteed Minimum: 100 Doses Minimum Order Size: 100 Doses

NDC # 46028-0208-01

Fed. Excise Tax: $0.75 per dose

Tentative future NDC effective October 1, 2016 – 58160-0955-09

1,400,000 Doses Tier 1: $85.22 (FET included) for Menveo ordered by HHS, the CDC and State Agencies, through the CDC ordering system until 200,000 doses of Bexsero are ordered.

Tier 2: $68.32 (FET included) for Menveo ordered by HHS, the CDC and State Agencies, through the CDC ordering system after 200,000 doses of Bexsero have been ordered.

$119,308,000.00

9. Rotavirus vaccine: Rotarix Min. Shelf Life: 12 Months Maximum Quantity: 1,600,000 Doses Guaranteed Minimum: 100 Doses Minimum Order Size: 100 Doses

NDC # 58160-0854-52

1,600,000 Doses

$86.75 (with FET

$138,800,000.00

10. Tdap vaccine: Boostrix Min. Shelf Life: 12 Months Maximum Quantity: 2,250,000 Doses Guaranteed Minimum: 100 Doses Minimum Order Size: 100 Doses

NDC # 58160-0842-11

850,000 doses

NDC # 58160-0842-52

1,400,000 doses Fed. Excise Tax: $2.25 per dose

2,250,000 Doses

$31.98 (with FET

$71,955,000.00

11. Meningococcal and Hib Vaccine Menhibrix (HibMenCY) Min. Shelf Life: 12 Months Maximum Quantity: 10,000 doses

10,000 Doses $10.53 (with FET

$105,300.00

Guaranteed Minimum: 100 Doses Minimum Order Size: 100 Doses

NDC # 58160-0801-11

Fed. Excise Tax: $1.50 per dose

12. Serogroup B Meninigococcal vaccine:

Bexsero Min. Shelf Life: 12 Months Maximum Quantity: 2,250,000 Doses Guaranteed Minimum: 100 Doses Minimum Order Size: 100 Doses

NDC # 46028-0114-02

200,000 doses

NDC # 46028-0114-01

800,000 doses Fed. Excise Tax: $.75 per dose

Tentative future NDC effective October 1, 2016 – 58160-0976-20 (package of 10 doses) 58160-0976-06 (Package of 1 dose)

1,000,000 Doses Tiered Price Tier 1: $122.95* (FET included) for Bexsero ordered by HHS, the CDC and State Agencies, through the CDC ordering system up to 200,000 doses.

Tier 2: $98.51 (FET included) for Bexsero ordered by HHS, the CDC and State Agencies, through the CDC ordering system up to the Maximum Quantity of 800,000 doses.

$103,398,000.00

Estimated total based on Maximum Doses $ 951,201,900.00

SECTION C - CONTRACT CLAUSES

C.1 52.212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders— Commercial Items.(MAR 2015)

(a) The Contractor shall comply with the following Federal Acquisition Regulation (FAR) clauses, which are incorporated in this contract by reference, to implement provisions of law or Executive orders applicable to acquisitions of commercial items:

(1) 52.209-10, Prohibition on Contracting with Inverted Domestic Corporations (Dec 2014)

(2) 52.233-3, Protest After Award (AUG 1996) (31 U.S.C. 3553).

(3) 52.233-4, Applicable Law for Breach of Contract Claim (OCT 2004) (Public Laws 108-77, 108-78 (19 U.S.C. 3805 note)).

(b) The Contractor shall comply with the FAR clauses in this paragraph (b) that the contracting officer has indicated as being incorporated in this contract by reference to implement provisions of law or Executive orders applicable to acquisitions of commercial items:

_X_ (1) 52.203-6, Restrictions on Subcontractor Sales to the Government (Sept 2006), with Alternate I (Oct 1995) (41 U.S.C. 4704 and 10 U.S.C. 2402).

_ X_ (2) 52.203-13, Contractor Code of Business Ethics and Conduct (Apr 2010) (41 U.S.C. 3509).

___ (3) 52.203-15, Whistleblower Protections under the American Recovery and Reinvestment Act of 2009 (Jun 2010) (Section 1553 of Pub L. 111-5) (Applies to contracts funded by the American Recovery and Reinvestment Act of 2009).

_X_ (4) 52.204-10, Reporting Executive compensation and First-Tier Subcontract Awards (Jul 2013) (Pub.

L. 109-282) (31 U.S.C. 6101 note).

___ (5) [Reserved]

___ (6) 52.204-14, Service Contract Reporting Requirements (Jan 2014) (Pub. L. 111-117, section 743 of Div. C).

___ (7) 52.204-15, Service Contract Reporting Requirements for Indefinite-Delivery Contracts (Jan 2014) (Pub. L. 111-117, section 743 of Div. C).

_X_ (8) 52.209-6, Protecting the Government’s Interest When Subcontracting with Contractors Debarred, Suspended, or Proposed for Debarment (Aug 2013) (31 U.S.C. 6101 note).

_X_ (9) 52.209-9, Updates of Publicly Available Information Regarding Responsibility Matters (Jul 2013) (41 U.S.C. 2313).

_X_ (10) 52.209-10, Prohibition on Contracting with Inverted Domestic Corporations (May 2012) (section 738 of Division C of Public Law 112-74, section 740 of Division C of Pub. L. 111-117, section 743 of Division D of Pub. L. 111-8, and section 745 of Division D of Pub. L. 110-161).

___ (11) (i) 52.219-3, Notice of HUBZone Set-Aside or Sole-Source Award (Nov 2011) (15 U.S.C. 657a).

___ (ii) Alternate I (Nov 2011) of 52.219-3.

_X_ (12) (i) 52.219-4, Notice of Price Evaluation Preference for HUBZone Small Business Concerns (Oct 2011) (if the offeror elects to waive the preference, it shall so indicate in its offer)(15 U.S.C. 657a).

___ (ii) Alternate I (Jan 2011) of 52.219-4.

___ (13) [Reserved]

___ (14) (i) 52.219-6, Notice of Total Small Business Aside (Nov 2011) (15 U.S.C. 644).

___ (ii) Alternate I (Nov 2011).

___ (iii) Alternate II (Nov 2011).

___ (15) (i) 52.219-7, Notice of Partial Small Business Set-Aside (June 2003) (15 U.S.C. 644).

___ (ii) Alternate I (Oct 1995) of 52.219-7.

___ (iii) Alternate II (Mar 2004) of 52.219-7.

_X_ (16) 52.219-8, Utilization of Small Business Concerns (Oct 2014) (15 U.S.C. 637(d)(2) and (3)).

_X_ (17) (i) 52.219-9, Small Business Subcontracting Plan (Oct 2014) (15 U.S.C. 637 (d)(4)).

___ (ii) Alternate I (Oct 2001) of 52.219-9.

___ (iii) Alternate II (Oct 2001) of 52.219-9.

___ (iv) Alternate III (Oct 2014) of 52.219-9.

___ (18) 52.219-13, Notice of Set-Aside of Orders (Nov 2011) (15 U.S.C. 644(r)).

___ (19) 52.219-14, Limitations on Subcontracting (Nov 2011) (15 U.S.C. 637(a)(14)).

_X_ (20) 52.219-16, Liquidated Damages—Subcontracting Plan (Jan 1999) (15 U.S.C. 637(d)(4)(F)(i)).

___ (21) 52.219-27, Notice of Service-Disabled Veteran-Owned Small Business Set-Aside (Nov 2011) (15 U.S.C. 657f).

_X_ (22) 52.219-28, Post Award Small Business Program Rerepresentation (Jul 2013) (15 U.S.C.

632(a)(2)).

___ (23) 52.219-29, Notice of Set-Aside for Economically Disadvantaged Women-Owned Small Business (EDWOSB) Concerns (Jul 2013) (15 U.S.C. 637(m)).

___ (24) 52.219-30, Notice of Set-Aside for Women-Owned Small Business (WOSB) Concerns Eligible Under the WOSB Program (Jul 2013) (15 U.S.C. 637(m)).

___ (25) 52.222-3, Convict Labor (June 2003) (E.O. 11755).

_X-__ (26) 52.222-19, Child Labor—Cooperation with Authorities and Remedies (Jan 2014) (E.O. 13126).

_X_ (27) 52.222-21, Prohibition of Segregated Facilities (Feb 1999).

_X_ (28) 52.222-26, Equal Opportunity (Mar 2007) (E.O. 11246).

_X_ (29) 52.222-35, Equal Opportunity for Veterans (Jul 2014) (38 U.S.C. 4212).

_X_ (30) 52.222-36, Equal Opportunity for Workers with Disabilities (Jul 2014) (29 U.S.C. 793).

_X_ (31) 52.222-37, Employment Reports on Veterans (Jul 2014) (38 U.S.C. 4212).

_X_ (32) 52.222-40, Notification of Employee Rights Under the National Labor Relations Act (Dec 2010) (E.O. 13496).

_X_ (33) (i) 52.222-50, Combating Trafficking in Persons (Mar 2015) (22 U.S.C. chapter 78 and E.O.

13627).

___ (ii) Alternate I (Mar 2015) of 52.222-50, (22 U.S.C. chapter 78 and E.O. 13627).

___ (34) 52.222-54, Employment Eligibility Verification (Aug 2013). (Executive Order 12989). (Not applicable to the acquisition of commercially available off-the-shelf items or certain other types of commercial items as prescribed in 22.1803.)

___ (35) (i) 52.223-9, Estimate of Percentage of Recovered Material Content for EPA-Designated Items (May 2008) (42 U.S.C. 6962(c)(3)(A)(ii)). (Not applicable to the acquisition of commercially available off-the-shelf items.)

___ (ii) Alternate I (May 2008) of 52.223-9 (42 U.S.C. 6962(i)(2)(C)). (Not applicable to the acquisition of commercially available off-the-shelf items.)

___ (36) (i) 52.223-13, Acquisition of EPEAT® -Registered Imaging Equipment (Jun 2014) (E.O.s 13423 and 13514

___ (ii) Alternate I (Jun 2014) of 52.223-13.

___ (37) (i) 52.223-14, Acquisition of EPEAT® -Registered Television (Jun 2014) (E.O.s 13423 and 13514).

___ (ii) Alternate I (Jun 2014) of 52.223-14.

___ (38) 52.223-15, Energy Efficiency in Energy-Consuming Products (Dec 2007) (42 U.S.C. 8259b).

___ (39) (i) 52.223-16, Acquisition of EPEAT® -Registered Personal Computer Products (Jun 2014) (E.O.s 13423 and 13514).

___ (ii) Alternate I (Jun 2014) of 52.223-16.

_X_ (40) 52.223-18, Encouraging Contractor Policies to Ban Text Messaging while Driving (Aug 2011) (E.O. 13513).

___ (41) 52.225-1, Buy American--Supplies (May 2014) (41 U.S.C. chapter 83).

___ (42) (i) 52.225-3, Buy American--Free Trade Agreements--Israeli Trade Act (May 2014) (41 U.S.C.

chapter 83, 19 U.S.C. 3301 note, 19 U.S.C. 2112 note, 19 U.S.C. 3805 note, 19 U.S.C. 4001 note, Pub. L.

103-182, 108-77, 108-78, 108-286, 108-302, 109-53, 109-169, 109-283, 110-138, 112-41, 112-42, and 112- 43).

___ (ii) Alternate I (May 2014) of 52.225-3.

___ (iii) Alternate II (May 2014) of 52.225-3.

___ (iv) Alternate III (May 2014) of 52.225-3.

___ (43) 52.225-5, Trade Agreements (Nov 2013) (19 U.S.C. 2501, et seq., 19 U.S.C. 3301 note).

_X_ (44) 52.225-13, Restrictions on Certain Foreign Purchases (Jun 2008) (E.O.’s, proclamations, and statutes administered by the Office of Foreign Assets Control of the Department of the Treasury).

___ (45) 52.225-26, Contractors Performing Private Security Functions Outside the United States (Jul 2013) (Section 862, as amended, of the National Defense Authorization Act for Fiscal Year 2008; 10 U.S.C. 2302 Note).

___ (46) 52.226-4, Notice of Disaster or Emergency Area Set-Aside (Nov 2007) (42 U.S.C. 5150).

___ (47) 52.226-5, Restrictions on Subcontracting Outside Disaster or Emergency Area (Nov 2007) (42 U.S.C. 5150).

_X_ (48) 52.232-29, Terms for Financing of Purchases of Commercial Items (Feb 2002) (41 U.S.C. 4505), 10 U.S.C. 2307(f)).

___ (49) 52.232-30, Installment Payments for Commercial Items (Oct 1995) (41 U.S.C. 4505, 10 U.S.C.

2307(f)).

___ (50) 52.232-33, Payment by Electronic Funds Transfer— System for Award Management (Jul 2013) (31 U.S.C. 3332).

___ (51) 52.232-34, Payment by Electronic Funds Transfer—Other Than System for Award Management (Jul 2013) (31 U.S.C. 3332).

___ (52) 52.232-36, Payment by Third Party (May 2014) (31 U.S.C. 3332).

___ (53) 52.239-1, Privacy or Security Safeguards (Aug 1996) (5 U.S.C. 552a).

___ (54) (i) 52.247-64, Preference for Privately Owned U.S.-Flag Commercial Vessels (Feb 2006) (46 U.S.C. Appx 1241(b) and 10 U.S.C. 2631).

___ (ii) Alternate I (Apr 2003) of 52.247-64.

(c) The Contractor shall comply with the FAR clauses in this paragraph (c), applicable to commercial services, that the Contracting Officer has indicated as being incorporated in this contract by reference to implement provisions of law or executive orders applicable to acquisitions of commercial items:

___ (1) 52.222-41, Service Contract Labor Standards (May 2014) (41 U.S.C. chapter 67.).

___ (2) 52.222-42, Statement of Equivalent Rates for Federal Hires (May 2014) (29 U.S.C. 206 and 41 U.S.C. chapter 67).

___ (3) 52.222-43, Fair Labor Standards Act and Service Contract Labor Standards -- Price Adjustment (Multiple Year and Option Contracts) (May 2014) (29 U.S.C.206 and 41 U.S.C. chapter 67).

___ (4) 52.222-44, Fair Labor Standards Act and Service Contract Labor Standards -- Price Adjustment (May 2014) (29 U.S.C. 206 and 41 U.S.C. chapter 67).

___ (5) 52.222-51, Exemption from Application of the Service Contract Labor Standards to Contracts for Maintenance, Calibration, or Repair of Certain Equipment--Requirements (May 2014) (41 U.S.C. chapter 67).

___ (6) 52.222-53, Exemption from Application of the Service Contract Labor Standards to Contracts for Certain Services--Requirements (May 2014) (41 U.S.C. chapter 67).

___ (7) 52.222-17, Nondisplacement of Qualified Workers (May 2014) (E.O. 13495).

___ (8) 52.226-6, Promoting Excess Food Donation to Nonprofit Organizations. (May 2014) (42 U.S.C.

1792).

___ (9) 52.237-11, Accepting and Dispensing of $1 Coin (Sep 2008) (31 U.S.C. 5112(p)(1)).

___ (10) 52.222-55, Minimum Wages Under Executive Order 13658 Dec 2014)(Executive Order 13658).

(d) Comptroller General Examination of Record The Contractor shall comply with the provisions of this paragraph

(d) if this contract was awarded using other than sealed bid, is in excess of the simplified acquisition threshold, and does not contain the clause at 52.215-2, Audit and Records -- Negotiation.

(1) The Comptroller General of the United States, or an authorized representative of the Comptroller General, shall have access to and right to examine any of the Contractor’s directly pertinent records involving transactions related to this contract.

(2) The Contractor shall make available at its offices at all reasonable times the records, materials, and other evidence for examination, audit, or reproduction, until 3 years after final payment under this contract or for any shorter period specified in FAR Subpart 4.7, Contractor Records Retention, of the other clauses of this contract. If this contract is completely or partially terminated, the records relating to the work terminated shall be made available for 3 years after any resulting final termination settlement. Records relating to appeals under the disputes clause or to litigation or the settlement of claims arising under or relating to this contract shall be made available until such appeals, litigation, or claims are finally resolved.

(3) As used in this clause, records include books, documents, accounting procedures and practices, and other data, regardless of type and regardless of form. This does not require the Contractor to create or maintain any record that the Contractor does not maintain in the ordinary course of business or pursuant to a provision of law.

(e)

(1) Notwithstanding the requirements of the clauses in paragraphs (a), (b), (c) and (d) of this clause, the Contractor is not required to flow down any FAR clause, other than those in this paragraph (e)(1) in a subcontract for commercial items. Unless otherwise indicated below, the extent of the flow down shall be as required by the clause—

(i) 52.203-13, Contractor Code of Business Ethics and Conduct (Apr 2010) (41 U.S.C. 3509).

(ii) 52.219-8, Utilization of Small Business Concerns (Oct 2014) (15 U.S.C. 637(d)(2) and (3)), in all subcontracts that offer further subcontracting opportunities. If the subcontract (except subcontracts to small business concerns) exceeds $650,000 ($1.5 million for construction of any public facility), the subcontractor must include 52.219-8 in lower tier subcontracts that offer subcontracting opportunities.

(iii) 52.222-17, Nondisplacement of Qualified Workers (May 2014) (E.O. 13495). Flow down required in accordance with paragraph (1) of FAR clause 52.222-17.

(iv) 52.222-26, Equal Opportunity (Mar 2007) (E.O. 11246).

(v) 52.222-35, Equal Opportunity for Veterans (Jul 2014) (38 U.S.C. 4212).

(vi) 52.222-36, Equal Opportunity for Workers with Disabilities (Jul 2014) (29 U.S.C. 793).

(vii) 52.222-37, Employment Reports on Veterans (Jul 2014) (38 U.S.C. 4212).

(viii) 52.222-40, Notification of Employee Rights Under the National Labor Relations Act (Dec 2010) (E.O. 13496). Flow down required in accordance with paragraph (f) of FAR clause 52.222- 40.

(ix) 52.222-41, Service Contract Labor Standards (May 2014), (41 U.S.C. chapter 67).

(x) __X_ (A) 52.222-50, Combating Trafficking in Persons (Mar 2015) (22 U.S.C. chapter 78 and E.O. 13627).

___ (B) Alternate I (Mar 2015) of 52.222-50 (22 U.S.C. chapter 78 E.O. 13627).

(xi) 52.222-51, Exemption from Application of the Service Contract Labor Standards to Contracts for Maintenance, Calibration, or Repair of Certain Equipment--Requirements (May 2014) (41 U.S.C. chapter 67.)

(xii) 52.222-53, Exemption from Application of the Service Contract Labor Standards to Contracts for Certain Services--Requirements (May 2014) (41 U.S.C. chapter 67)

(xiii) 52.222-54, Employment Eligibility Verification (Aug 2013).

(xiv) 52.225-26, Contractors Performing Private Security Functions Outside the United States (Jul 2013) (Section 862, as amended, of the National Defense Authorization Act for Fiscal Year 2008;

10 U.S.C. 2302 Note).

(xv) 52.226-6, Promoting Excess Food Donation to Nonprofit Organizations. (May 2014) (42 U.S.C. 1792). Flow down required in accordance with paragraph (e) of FAR clause 52.226-6.

(xvi) 52.247-64, Preference for Privately-Owned U.S. Flag Commercial Vessels (Feb 2006) (46 U.S.C. Appx 1241(b) and 10 U.S.C. 2631). Flow down required in accordance with paragraph (d) of FAR clause 52.247-64.

(xvii) 52.222-55, Minimum Wages Under Executive Order 13658 (Dec 2014)(Executive Order 13658).

(2) While not required, the contractor may include in its subcontracts for commercial items a minimal number of additional clauses necessary to satisfy its contractual obligations.

C.2 The following FAR Clause is incorporated by reference:

FAR SOURCE TITLE AND DATE

52.212-4 Contract Terms and Conditions—Commercial Items (Dec 2014) 52.232-1 Payments

C.3 Special Clauses

C.3.1. Shelf Life

Vaccine provided under this contract shall have a minimum 12 month shelf life remaining upon delivery to the consignee, or as specified within each Contract Line Item Number (See Section B, Continuation of SF 1449).

C.3.2. Packaging and Packing Requirements

1. Packaging:

All items shall be packaged in standard commercial manner.

2. Packing:

a. Product shall be packed to ensure maintenance of FDA recommended temperature during transit and safe arrival at destination. An electronic temperature monitoring device is required with each shipment unless Contractor has obtained prior approval from CDC to use an alternative monitoring method.

b. Contractor will provide the Contracting Officer Representative (COR) with documentation that explains the cause of each temperature excursion and stability data used by the contractor to determine if the cold chain was adversely affected by temperature variance. Upon review of data provided, CDC will notify appropriate parties if the vaccine is accepted or rejected.

C.3.3. Contract Period of Performance

The contract period of performance shall begin on the date of award and shall end March 31, 2017.

C.3.4. Time of Delivery

Delivery is required to be made at destination within 15 working days after receipt of electronic, written, or telephonic order (telephone orders to be confirmed in writing).

C.3.5. Place of Delivery

The Contractor shall be required to deliver vaccines F.O.B. Destination, as directed by delivery orders to the CDC centralized distribution locations currently in Aurora, CO and Memphis, TN.

The Contractor shall be required to deliver frozen vaccines F.O.B. destination as directed by delivery orders.

C.3.6. Amendment to OBRA Statute

In the event of an amendment of 42 U.S.C. Section 1396(s), any terms of the contract affected by such an amendment will be modified in accordance with the revised statute. The Contracting Officer and the Contractor shall meet to discuss such modifications to the contract before finalization of any changes to the contract.

C.3.7. Product Licensure

a. The vaccines produced and delivered under this contract shall be manufactured under a current establishment and product license issued by the Food and Drug Administration as indicated below:

b. The Current Good Manufacturing Practice Regulations (CGMPR’s) (21CFR Parts 210, 211) will be the standard to be applied for manufacturing, processing and packing of drugs, chemicals, biologicals, and reagents.

c. The Contractor shall advise the Contracting Officer immediately of any relocation of his prime manufacturing facility or the relocation of any subcontractor’s facility, and if at any time during the life of the contract, the item listed under this contract fails to meet CGMPR’s and/or a negative Food and Drug Administration Quality Assurance Evaluation is received; the contract may be terminated, in whole or in part, without further liability to the Government.

C.3.8. Placement of Orders

a. All vaccine under this contract will be ordered by delivery orders. Orders shall be placed by Health and

Human Services (HHS), the Centers for Disease Control and Prevention (CDC) on behalf of eligible awardees or by the awardees. Orders shall be placed by electronic transfer. In the event of an emergency, orders may be placed by CDC by telephone (confirmed in writing). Contractors shall be able to interface with the CDC Electronic Vaccine Ordering System. If unable to interface at the time of award, the vendor shall complete interface implementation by the end of the period of performance of the contract.

b. Orders shall be submitted to the Ordering Address specified in Contract Clauses Paragraph C.3.12, Contractor’s Ordering/Payment Address, and shall contain the following minimum information:

1. Date of order;

2. Contract number and order number;

3. Item description, quantity and unit price;

4. Delivery or performance date;

5. Place of delivery or performance (including consignee);

6. Packaging, packing and shipping instruction, if any;

7. Accounting and appropriation data;

8. Statement to indicate if partial deliveries are not acceptable; (lack of a statement shall be construed to mean partial deliveries are acceptable and payment shall be made as required elsewhere herein)

9. Any other pertinent data.

C.3.9. Delivery Order Limitations

a. Minimum Order Size: Individual delivery orders issued under this contract must meet the minimum order size as specified within each Contract Line Item Number (See Section B, Continuation of SF 1449). When the Government requires supplies covered by this contract in amounts less than stated above, the Government is not obligated to purchase, nor is the Contractor obligated to furnish those supplies under this contract.

b. Maximum Order: The maximum quantity specified within each Contract Line Item Number (See Section

B, Continuation of SF1449) is the maximum number of doses that may be ordered during the contract period of performance. Contractors are advised that the maximum quantity represents their commitment to the CDC under their contract.

c. Delivery Orders shipments:

1. Shipments shall be sent with all transaction information necessary to be compliant with applicable

Drug Supply Chain Security Act requirements regarding Transaction Information (TI), Transaction History (TH), and Transaction Statement (TS). Initially paper documentation or portal access will be acceptable, but EDI messaging between contractors and CDC will transition to allow electronic transmission of information.

2. The Government reserves the right to reject vaccine doses that exceed delivery order requirements.

The Government shall notify the Contractor when excess doses have been delivered to distribution sites. The Contractor is responsible for contacting the distribution site to make arrangement for the return of the excess doses and will be responsible for shipping cost associated with their return.

3. Bulk order shipments, when possible, shall consist of

a. One NDC per skid

b. Full skid quantities with same lot number

c. Full case quantities (when total order size allows)

C.3.10. FAR 52.216-18. Ordering (Oct 1995)

a. Any supplies and services to be furnished under this contract shall be ordered by issuance of delivery orders or task orders by the individuals or activities designated in the Schedule. Such orders may be issued from the effective date of the contract through the expiration date of the contract.

b. All delivery orders or task orders are subject to the terms and conditions of this contract. In the event of conflict between a delivery order or task order and this contract, the contract shall control.

c. If mailed, a delivery order or task order is considered “issued” when the Government deposits the order in the mail. Orders may be issued orally or by written telecommunications only if authorized in the Schedule.

C.3.11. FAR 52.216-22 Indefinite Quantity (Oct 1995)

a. This is an indefinite quantity contract for the supplies specified and effective for the period stated in the

Schedule. The quantities of supplies and services specified in the Schedule are estimates only and are not purchased by this contract.

b. Delivery or performance shall be made only as authorized by orders issued in accordance with the

Ordering clause. The Contractor shall furnish to the Government, when and if ordered, the supplies specified in the Schedule up to and including the quantity designated in the Schedule as the “maximum.”

The Government shall order at least the quantity of supplies designated in the Schedule as the “minimum.”

c. Except for any limitations on quantities in the Delivery Order Limitations clause or in the Schedule, there is no limit on the number of orders that may be issued. The Government may issue orders requiring delivery to multiple destinations or performance at multiple locations.

d. Any order issued during the effective period of this contract and not completed within that period shall be completed by the Contractor within the time specified in the order. The contract shall govern the Contractor’s and Government’s rights and obligations with respect to that order to the same extent as if the order were completed during the contract’s effective period; provided, that the Contractor shall not be required to make any deliveries under this contract after fifteen (15) working days beyond the expiration date of the contract.

C.3.12. Contractor's Ordering/Payment Address

Submission of all orders for Contractor’s vaccines and payment of invoices shall be addressed as referenced below:

Ordering Address Payments Address

GlaxoSmithKline GlaxoSmithKline Vaccine Service Center PO Box 740415

5 Crescent Drive Atlanta, GA 30374-0415 Philadelphia, PA 19112

C.3.13. Invoice Submission

1. Invoice submission under this contract will be made as follows:

a. Federal Government: The Contractor shall submit invoices via Electronic Data Interchange (EDI).

b. Awardees: The Contractor shall submit one hard copy of its invoice(s) to the address specified on the delivery order.

c. The Contractor agrees to include the following information on each invoice:

1. Contractor’s name and invoice date;

2. Contract number, or other authorization for delivery of property and/or services;

3. Description, cost or price, and quantity of property and/or services actually delivered or rendered;

4. Shipping and payment terms;

5. Other substantiating documentation or information as required by the contract;

6. Name where practicable, title, phone number, and complete mailing address of responsible official to whom payment is to be sent;

7. NDC and Lot number of vaccine shipped;

8. CDC accounting and appropriation data as described on the delivery order; and

9. Electronic Funds Transfer (EFT) and Taxpayer Identification Number (TIN).

C.3.14. Method of Payment

a. Federal Government: The Government will use electronic funds transfer when making payment under this contract IAW/FAR Clause 52.232-33, payment by Electronic Funds Transfer - Central Contractor Registration.

b. Awardees: By check. The Government is not liable for payment related to orders submitted by states, cities, or territories.

C.3.15. Contract Officer Representative (COR)

A COR will be designated in writing by the Contracting Officer to serve during the period of performance of the contract. The COR shall be responsible for guidance in regard to the technical aspect of the contract, provide a point for liaison between the Contractor and other Government agencies and be the general focal point to address technical and logistical problems relating to the performance under the contract. The COR shall not have the authority to make any commitments or authorize any changes which affect the contract price, terms and/or conditions; any such changes shall be referred to the Contracting Officer for action.

C.3.16. Return Privileges

Return privileges for credit, reimbursement or exchange do not apply to this contract except vaccines not conforming to the specifications set forth herein.

C.3.17. Restrictions on Use of Vaccines

Vaccines obtained under this contract shall be used only in children 18 years of age and younger as authorized under Section 1928 of the Social Security Act. Sale of such vaccine to any person or entity or reimbursement of vaccine costs is strictly prohibited. Free distribution of such vaccine is also prohibited, except where such vaccine is administered in the context of Federal and Awardee immunization program activities.

C.3.18. Federal Excise Tax Credit

Negotiated prices for the vaccines included in this Contract may include a Federal Excise Tax (See Continuation of SF 1449 for applicable Contract Line Item Numbers). If for any reason the vaccine is returned (other than for resale) or destroyed, the Contractor shall within 6 months following the date the vaccine is returned or destroyed, file a claim for credit or refund relative to any tax previously paid on such vaccine. The Contractor agrees to credit or refund the amount of such excise tax to the purchaser to the extent that the Contractor receives a credit or refund from the Federal Government. Any such credit or refund to the purchaser is expressly conditioned upon the authorized purchaser providing a written summary of events leading to the request for credit or refund. The purchaser shall return all undistributed vaccine to the Contractor for proper disposal, unless destruction of the vaccine renders return impossible. If destruction of the vaccine renders return impossible and is therefore destroyed by the purchaser, the authorized purchaser must provide a written summary of events to the Contractor within 30 days of said destruction. If a contract is in place with the Contractor at the time when a credit or refund is due; the purchaser may elect to receive vaccine which will be purchased at the current contract price in lieu of a cash payment. Otherwise, the Contractor shall refund the amount due to the purchaser’s account. If a credit or refund is issued by the Contractor for state or local funds, it shall be submitted to the state or local public health entity identified in the request for FET credit. If a credit or refund is issued by the Contractor to the Federal Funds account, it shall contain the Contractor’s DUNS and TIN/EIN and shall be submitted either via EDI (for credit) or to the following address (for check):

Centers for Disease Control and Prevention Office of Financial Resources (OFR) Attn: Debt Management Branch P.O. Box 15580 Atlanta, GA 30329-4027

C.3.19. Delinquent Delivery Report

The Contractor shall provide CDC with a weekly electronic listing of all CDC orders that have not been shipped within the agreed upon delivery schedule. The report shall include the following information: order number, date of order, and status of order in number of pending/undelivered doses. The report shall also provide an explanation as to the cause for the delinquent delivery as well as when the vaccine will be delivered. This notification shall not relieve the contractor from meeting its obligations under the contract and shall not limit the Government’s right to seek relief for any breach of contract for failure to perform, including termination for cause.

C.3.20. Biological Surveillance Data Reports

a. The Contractor shall submit a monthly report of historical sales data for the United States by month and state, specifying the name of the vaccine, NDC #, and the total number of doses sold (segregated by CDC and non-CDC sales), in a standardized format acceptable to the Contractor and the CDC. The report shall be submitted electronically to the COR by the 15th of the month. Information related to vaccine sales through CDC contracts is not considered proprietary. CDC acknowledges that those reports pertaining to private sales unrelated to this contract are confidential and proprietary information of the Contractor, and shall not use reports for any purpose other than CDC’s internal tracking and reporting purposes and shall not further disclose such reports without the Contractor’s prior written consent unless required by the law or other Federal authority; provided that, no Contractor authorization shall be required for the CDC to include the data from the Contractor’s report in a report in which aggregated data from multiple Contractors is summarized, so long as, with respect to multi-sourced products, the CDC’s aggregated report does not include any data which could be individually identified as the Contractor’s. In the event that CDC is required by law or other Federal authority to disclose such reports required to be held confidential hereunder, CDC shall notify the Contractor prior to making such disclosure in accordance with law or other Federal authority.

b. Data Reports to Manufacturers

The Government will submit monthly reports of all vaccine data specifying doses by project, zip code, and NDC # in a standardized format. For all vaccines except direct ship vaccines, the Government shall provide distribution data. Because the Government does not distribute direct ship vaccines, purchase data will be provided. The reports shall be submitted electronically to the Contractor by the 15th of the month for the previous month. The Government shall also provide the Contractor with an annual Vaccine Tracking System (VTrckS) spend plan for each Awardee and an annual providers list during the first quarter of the fiscal year.

C.3.21. Prohibitions on Inducements

The Contractor is expressly prohibited from offering, providing or arranging inducements of any kind to providers or authorized purchasers ordering vaccine under this contract for the purpose of obtaining orders for vaccine.

Examples of such inducements include, but are not limited to: entertainment, meals, and free or reduced prices for syringes, vaccines, or other medical products or supplies. If the Contractor has entered into similar agreements with the authorized purchasers which offer inducements relative to its commercial business, these agreements must be clear that they do not apply to purchases made under the CDC Federal contracts.

C.3.22. Contract Changes

Notwithstanding FAR Clause 52.212-4(c), Changes, the parties hereby agree that modifications for incremental funding and other administrative changes (e.g., changes to CDC accounting data) that do not affect the terms and conditions of the contract may be made unilaterally by the CDC.

C.3.23. Vaccine images

Upon contract award, the Contractor agrees to provide via email camera-ready vaccine product images in .pdf format and written authorization for CDC to use the images to the COR. CDC will use the images to illustrate the Contractor’s products on the CDC vaccine ordering system. The Contractor agrees to provide CDC with updated product images if there is a change in packaging and vaccine images for new NDCs added to the contract during the period of performance.

For each vaccine furnished under this contract, complete the information in the template below, including the NDC numbers for the unit of sale and unit(s) of use in the first and last columns. If there is more than one component/NDC within the unit of use, list each NDC separately along with component name.

Unit of Sale (Box/Carton) Unit of Use (Vial/Syringe)

NDC Brandname/ Tradename

Description/Presentation NDC

58160-0842-11 BOOSTRIX Single Dose 0.5mL Vial (10) 58160-0842-01

58160-0842-52 BOOSTRIX 0.5mL Prefilled Tip-Lok™ Syringe w/out needles (10)

58160-0842-43

58160-0810-11 INFANRIX Single Dose 0.5mL Vial (10) 58160-0810-01

58160-0810-52 INFANRIX 0.5 mL Prefilled Tip-Lok™ Syringe w/out needles (10)

58160-0810-43

58160-0811-52 PEDIARIX 0.5mL Prefilled Tip-Lok™ Syringe w/out needles (10)

58160-0811-43

58160-0820-11 ENGERIX B Single Dose 10mcg/0.5mL Vial (10) 58160-0820-01

58160-0820-52 ENGERIX B 10mcg/0.5mL Prefilled Tip-Lok™ Syringe w/out needles (10)

58160-0820-43

58160-0825-11 HAVRIX Single Dose 720 EL.U./0.5mL Vial (10) 58160-0825-01

58160-0825-52 HAVRIX 720 EL.U./0.5mL, Prefilled Tip-Lok™ Syringe w/out needles (10)

58160-0825-43

58160-0854-52 ROTARIX Oral Suspension (10) 58160-0851-01

58160-0801-11 MENHIBERIX Single dose vials of lyophilized vaccine, accompanied by vials containing 0.85 mL of saline diluent (10)

Lyo vaccine 58160-0809-01

Saline Dil 58160-0813-01

58160-0812-11 KINRIX Single Dose 0.5mL Vial (10) 58160-0812-01

58160-0812-52 KINRIX 0.5mL Prefilled Tip-Lok™ Syringe w/out needles (10)

58160-0812-43

58160-0815-52 TWINRIX 720 EL.U./mL Prefilled Tip-Lok™ Syringe w/out needles (10)

58160-0815-43

58160-818-11 HIBERIX Single dose vials of lyophilized vaccine, accompanied by vials containing 0.85 mL of saline diluent (10) (packaged without syringes or Needles)

NDC 58160-816-01

Vial of lyophilized vaccine in Package of 10: 58160-816-05

NDC 58160-817-01

Vial of saline diluent in Package of 10: 58160-817-05

46028-0208-01 MENVEO Meningococcal Conjugate(Groups A, C, Y and W-135) (5)

MenA lyo conjugate vaccin:

46028-0218-11

MenCYW-135 liquid Conjugate: 46028-0219-11

58160-0955-09 MENVEO

(Tentatively effective 10/1/16)*

Meningococcal Conjugate(Groups A, C, Y and W-135) (5)

5 vials containing MenA lyophilized conjugate component

NDC 58160-958-01

5 vials containing MenCYW- 135 liquid conjugate component

NDC 58160-959-01

58160-0976-20 BEXSERO

(Tentatively effective 10/1/16)*

0.5mL single dose syringe (10) 58160-0976-02

58160-0976-06 BEXSERO

(Tentatively effective 10/1/16)*

0.5mL single dose syringe (1) 58160-0976-02

*Pending FDA Approval

C.3.24. Advance Notice of Supply Issues

The Contractor agrees to provide advance notification to COR and the CDC Contracting Officer of any supply issue which may result in the Contractor’s failure to deliver vaccine within the agreed upon delivery schedule specified in the contract. This notification shall be given as soon as the Contractor becomes aware of the scope of the problem that will impede the timely delivery of vaccine. This notification shall not relieve the contractor from meeting its obligations under the contract and shall not limit the Government’s right to seek relief for any breach of contract for failure to perform, including termination for cause. Furthermore, any deviation from the delivery schedule due to a vaccine supply issue will demonstrate reasonably equal treatment with respect to the fulfillment of orders between CDC and the contracting non-government customers.

C.3.25. Authorized Distribution of Record (ADR) Agreements

In accordance with the Prescription Drug Marketing Act (PDMA) of 1998, it is requested that all suppliers provide a written statement included as an attachment in Section D of this solicitation, which designates the CDC as the ADR for all vaccines subject to distribution under this contract.

C.3.26. Use of VFC Provider Lists and Distribution of Material

a. Contractors are prohibited from utilizing VFC providers lists obtained from any source for any mailing or other communication with VFC providers, except as approved in writing by the CDC COR. In addition, contractors are prohibited from otherwise communicating with VFC providers regarding the VFC program, except as approved in writing by the CDC COR. To the extent that Contractors have established relationships with VFC providers or authorized purchasers under this contract that are independent from the VFC program, communications related to such independent relationships are not covered by this provision and do not require CDC consent.

b. Contractors are prohibited from providing names and/or addresses of VFC providers to any third party, except as needed to comply with the terms of this contract, in which cases the CDC COR shall be notified in writing.

c. Any Contractor that ships vaccine directly to VFC providers is prohibited from inserting any promotional or other material that is promotional in nature for any product that the Contractor produces, into shipping containers for vaccine purchased under this contract, except for material related to use of the vaccine as approved in writing by the CDC COR. Additionally any shipping container inserts that are required, such as handling instructions or educational materials, should not contain any promotional material as part of its content.

C.3.27. New FDA Product License

Manufacturers who receive a new FDA product license for a vaccine already included within the scope of a VFC resolution may have the new product added to its contract by modification if it is determined that adding the product is in the best interest of the Government. Such new products must be consistent with VFC formulary schedules (regarding periodicity and dosage regimens) as established for the vaccines by the Advisory Committee on Immunization Practices (ACIP). New FDA licensed products added to this contract must comply with Clause C.3.29., Price Changes, below.

C.3.28. ACIP Approved Product

When a new vaccine product is approved by the ACIP for inclusion in the VFC Formulary, the Manufacturer of such product may have the new product added to its contract by modification if it is determined that adding the product is in the best interest of the Government. This would include new vaccines, new indications or new formulations for existing products or new dosing regimens for an existing product. New FDA licensed products added to this contract must comply with Clause C.3.29., Price Changes, below.

C.3.29. Price Changes

All price change effective dates shall be approved by the CDC Contracting Officer and shall occur on the first day of the following month.

C.3.30. Evaluation of Contractor Performance Utilizing CPARS (April 2013)

In accordance with FAR 42.15, the Centers for Disease Control and Prevention (CDC) will review and evaluate contract performance. FAR 42.1502 and 42.1503 requires agencies to prepare evaluations of contractor performance and submit them to the Past Performance Information Retrieval System (PPIRS). The CDC utilizes the Department of Defense (DOD) web-based Contractor Performance Assessment Reporting System (CPARS) to prepare and report these contractor performance evaluations. All information contained in these assessments may be used by the Government, within the limitations of FAR 42.15, for future source selections in accordance with FAR

15.304 where past performance is an evaluation factor.

The CPARS system requires a contractor representative to be assigned so that the contractor has appropriate input into the performance evaluation process. The CPARS contractor representative will be given access to CPARS and will be given the opportunity to concur or not-concur with performance evaluations before the evaluations are complete. The CPARS contractor representative will also have the opportunity to add comments to performance evaluations.

The assessment is not subject to the Disputes clause of the contract, nor is it subject to appeal beyond the review and comment procedures described in the guides on the CPARS website.